﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropharmacology</JournalTitle>
      <Issn>2345-4202</Issn>
      <Volume>9</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2020</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Investigation of factors related to N-terminal pro-B type natriuretic peptide levels in hemodialysis patients; a single center study</ArticleTitle>
    <FirstPage>e05</FirstPage>
    <LastPage>e05</LastPage>
    <ELocationID EIdType="doi">10.15171/npj.2020.05</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Farbod</FirstName>
        <LastName>Bonakdar</LastName>
      </Author>
      <Author>
        <FirstName>Pegah</FirstName>
        <LastName>Noorshargh</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-0430-9286</Identifier>
      </Author>
      <Author>
        <FirstName>Parin</FirstName>
        <LastName>Hedayati</LastName>
      </Author>
      <Author>
        <FirstName>Hamid</FirstName>
        <LastName>Nasri</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-1673-5741</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/npj.2020.05</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2019</Year>
        <Month>03</Month>
        <Day>05</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>06</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Introduction: N-terminal pro-B type natriuretic peptide (NT-proBNP) can be used to diagnose cardiac and renal disease. The association of NT-pro BNP with demographic, clinical and biochemical factors in hemodialysis is unclear. Objectives: This study aimed to examine association of NT-pro BNP and mentioned factors in hemodialysis patients. Patients and Methods: This study was conducted on 78 end-stage renal disease (ESRD) patients under hemodialysis. Demographic data, lipid profile and electrolytes were recorded. NT-proBNP was checked simultaneously and its association with mentioned factors were assessed. Results: The average NT-pro BNP level was 890.52±700.87 pg/mL (range: 0.1-3343 pg/mL). Serum level of NT-pro BNP was statistically in association with total cholesterol (P=0.002; r=-0.348), low density lipoprotein (LDL) (P=0.09; r= -0.292), high density lipoprotein (HDL) (P=0.06; r=-0.310) and serum triglyceride (P=0.018; r=-0.269) while having a direct relationship with serum ferritin (P=0.022; r=0.274), alkaline phosphatase (ALP) (P=0.048; r=0.224) and duration of hemodialysis (P=0.005; r=0.321). Conclusion: Lipid profile and ferritin are associated with NT-pro BNP levels. This can reflect possible prognostic role of NT-proBNP among ESRD patients on hemodialysis.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">N-terminal pro-B type natriuretic peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Renal insufficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Renal dialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">End-stage renal disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic kidney disease</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>